CellBio Scientific Appoints Charles Miller as Founding CEO to Lead Post-Acquisition Growth and Innovation

PALO ALTO, Calif. — CellBio Scientific, a leading global provider of advanced tools and services for biomedical research and preclinical discovery, is excited to announce the appointment of Charles Miller as Chief Executive Officer, effective March 31, 2025. Dr. Miller will lead the company’s growth following recent strategic acquisitions and spearhead efforts to scale the business, deepen market impact, and unlock new customer value across life sciences research and drug discovery.

With more than 15 years of leadership experience in drug discovery, diagnostics, and preclinical services, Miller brings a proven track record of transforming organizations and delivering sustainable growth. His previous roles at The Jackson Laboratory and Elephas Biosciences included leading global commercial operations with revenues exceeding $500 million, brand-building in life science and drug discovery and driving market expansion into more than 70 countries.

“I’m honored to join CellBio Scientific at such a pivotal moment in its journey,” said Miller. “The opportunity to unify exceptional teams, build on a foundation of scientific excellence, and scale solutions that truly advance human health is both exciting and urgent. I look forward to working closely with our customers, partners, and employees to drive innovation, unlock new markets, and shape the future of drug discovery and human health.”

Miller holds a BS and PhD in biomedical sciences from The University of Michigan and Michigan State University, respectively, and an MBA from Yale. His management style is characterized by clarity, resilience, and a commitment to building high-performance cultures that deliver measurable impact.

“Charles is exactly the leader we need to drive CellBio Scientific into its next phase of growth,” said Mark Hilderbrand, CellBio Board of Directors Chair and Housatonic Partners Managing Director. “His experience scaling global life sciences platforms, coupled with a deep scientific understanding and a bold vision for innovation, makes him uniquely suited to lead this business forward. Under his leadership, we are confident CellBio will continue to deliver exceptional value to its customers and investors.”

Miller succeeds an interim leadership team that guided the company through a critical phase following formation and recent acquisitions. His appointment signals the company’s readiness to accelerate execution on its strategic roadmap, expand into new verticals, and continue building a world-class portfolio of drug discovery tools and services.

About CellBio Scientific

CellBio Scientific is a premier provider of life science tools, research services, and clinical solutions advancing the frontiers of biomedical discovery. Formed through the strategic integration of System Biosciences (SBI) and Acepix Biosciences, the company offers a comprehensive portfolio spanning biospecimens, spatial biology, extracellular vesicle technologies, gene delivery systems, cell-based models, and preclinical and clinical histopathology services. With a deep commitment to scientific excellence and innovation, CellBio Scientific empowers researchers, biopharma partners, and clinicians to drive breakthroughs in human health.

< | >